Studies have demonstrated that PDL1 was a direct target of the ER BRD4 and the expression inhibition of BRD4 could promote anti‐tumour immunity by modulating PDL1 expression in epithelial ovarian cancer.35 This evidence concerns the gene CD274 and neoplasm.